vs
Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
DYNEX CAPITAL INC is the larger business by last-quarter revenue ($43.5M vs $34.1M, roughly 1.3× ZEVRA THERAPEUTICS, INC.). On growth, DYNEX CAPITAL INC posted the faster year-over-year revenue change (531.3% vs 183.4%). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs 75.8%).
Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
DX vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.5M | $34.1M |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | — | 27.3% |
| Net Margin | — | — |
| Revenue YoY | 531.3% | 183.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | $1.59 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.5M | $34.1M | ||
| Q3 25 | $30.6M | $26.1M | ||
| Q2 25 | $23.1M | $25.9M | ||
| Q1 25 | $17.1M | $20.4M | ||
| Q4 24 | — | $12.0M | ||
| Q3 24 | — | $3.7M | ||
| Q2 24 | — | $4.4M | ||
| Q1 24 | $-3.2M | $3.4M |
| Q4 25 | — | — | ||
| Q3 25 | $150.4M | $-544.0K | ||
| Q2 25 | $-13.6M | $74.7M | ||
| Q1 25 | $-3.1M | $-3.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-33.2M | ||
| Q2 24 | — | $-19.9M | ||
| Q1 24 | $40.1M | $-16.6M |
| Q4 25 | — | 27.3% | ||
| Q3 25 | — | 15.9% | ||
| Q2 25 | — | -274.5% | ||
| Q1 25 | — | -26.3% | ||
| Q4 24 | — | -128.0% | ||
| Q3 24 | — | -739.0% | ||
| Q2 24 | — | -534.8% | ||
| Q1 24 | — | -598.1% |
| Q4 25 | — | — | ||
| Q3 25 | 491.3% | -2.1% | ||
| Q2 25 | -58.8% | 288.7% | ||
| Q1 25 | -18.0% | -15.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -899.2% | ||
| Q2 24 | — | -447.9% | ||
| Q1 24 | -1256.8% | -485.3% |
| Q4 25 | $1.59 | — | ||
| Q3 25 | $1.08 | $-0.01 | ||
| Q2 25 | $-0.14 | $1.21 | ||
| Q1 25 | $-0.06 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.69 | ||
| Q2 24 | — | $-0.48 | ||
| Q1 24 | $0.64 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $531.0M | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $2.5B | $154.7M |
| Total Assets | $17.3B | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $531.0M | $62.4M | ||
| Q3 25 | $491.0M | $54.4M | ||
| Q2 25 | $387.5M | $47.7M | ||
| Q1 25 | $327.4M | $37.3M | ||
| Q4 24 | — | $33.8M | ||
| Q3 24 | — | $54.0M | ||
| Q2 24 | — | $39.3M | ||
| Q1 24 | $295.7M | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $59.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.5B | $154.7M | ||
| Q3 25 | $2.0B | $133.2M | ||
| Q2 25 | $1.6B | $117.2M | ||
| Q1 25 | $1.4B | $41.0M | ||
| Q4 24 | — | $39.7M | ||
| Q3 24 | — | $69.8M | ||
| Q2 24 | — | $32.5M | ||
| Q1 24 | $958.5M | $48.8M |
| Q4 25 | $17.3B | $284.7M | ||
| Q3 25 | $14.2B | $270.1M | ||
| Q2 25 | $11.3B | $256.3M | ||
| Q1 25 | $9.0B | $172.7M | ||
| Q4 24 | — | $178.1M | ||
| Q3 24 | — | $191.6M | ||
| Q2 24 | — | $144.4M | ||
| Q1 24 | $6.3B | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.8M | $5.5M |
| Free Cash FlowOCF − Capex | — | $5.5M |
| FCF MarginFCF / Revenue | — | 16.1% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.8M | $5.5M | ||
| Q3 25 | $68.3M | $4.7M | ||
| Q2 25 | $31.9M | $-3.6M | ||
| Q1 25 | $6.4M | $-8.2M | ||
| Q4 24 | — | $-16.3M | ||
| Q3 24 | — | $-18.1M | ||
| Q2 24 | — | $-19.1M | ||
| Q1 24 | $-17.1M | $-16.2M |
| Q4 25 | — | $5.5M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | — | $-3.8M | ||
| Q1 25 | — | $-8.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 16.1% | ||
| Q3 25 | — | 15.9% | ||
| Q2 25 | — | -14.7% | ||
| Q1 25 | — | -40.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | — | -0.05× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DX
Segment breakdown not available.
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
